Sandra Lopez-Leon
Research Subjects
Research Interests
Sandra Lopez-Leon has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Talia Wegman-Ostrosky
Precision Medicine Laboratory, Instituto Nacional de Cancerología, Mexico City, Mexico
7 shared publications - Angelica Cuapio
Department of Medicine (Huddinge) Karolinska Institutet Stockholm Sweden
6 shared publications - Diego A. Forero
School of Health and Sport Sciences, Fundación Universitaria del Área Andina, Bogotá, Colombia
6 shared publications - Carol Perelman
Universidad Nacional Autónoma de México (UNAM), SOMEDICyT, RedMPC, Mexico City, Mexico
4 shared publications - Paulina Alejandra Rebolledo
Emory University School of Medicine
4 shared publications - Rosalinda Sepulveda
Harvard T.H. Chan School of Public Health Boston
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Algorithms to Identify Preeclampsia in Routinely Collected Healthcare Data: A Systematic Review
Importance: Preeclampsia is a leading cause of maternal morbidity and mortality globally. As real‐world data sources are increasingly used for maternal health surveillance and pharmacoepidemiologic studies, valid algorithms are essential for accurately identifying preeclampsia in routinely collected healthcare data. Objective: To identify and characterize algorithms used to ascertain preeclampsia in population‐based healthcare databases, summarize validation metrics, and describe the range of reported prevalence estimates. Evidence Review: Following PRISMA guidelines of 2021, PubMed was searched for studies published from January 1, 2010, to July 1, 2025. Observational studies using reproducible code‐based algorithms to identify preeclampsia in routinely collected healthcare data were included. Screening and full‐text review were performed in duplicate, with discrepancies resolved by a third reviewer. Data extraction focused on algorithm definitions, coding systems, validation methods, and epidemiologic estimates. A total of 289 studies met inclusion criteria, including 13 validation studies. Findings: Across included studies, 43.6% used Nordic nationwide registries, 30.1% used claims databases, and 12.1% used electronic health records. ICD‐10 O14.x was used in nearly all studies; inclusion of O11.x and O15.x varied. Validation studies consistently demonstrated high specificity (> 90%) but low sensitivity (≤ 80%), reflecting under‐ascertainment when relying solely on diagnosis codes. More than 70% of studies did not report start or end points for the time window of ascertainment. Reported prevalence ranged from 0.6% to 6.6% across case definitions and settings. The prevalence of severe preeclampsia ranged from 0.6% to 2.2%. Algorithms including O11.x, O14.x, and O15.x showed improved sensitivity in some settings. Conclusions and Relevance: Algorithms for identifying preeclampsia in real‐world data are highly specific but variably sensitive, with substantial heterogeneity in coding definitions and ascertainment windows. Standardized reporting and consistent inclusion of O11.x, O14.x, and O15.x may improve comparability, reproducibility, and the accuracy of epidemiologic estimates across data sources. High‐specificity algorithms may be particularly useful for comparative safety studies, whereas potential under‐ascertainment should be considered when estimating incidence or prevalence.
- 9 October 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Open AccessAlgorithms to Identify Preeclampsia in Routinely Collected Healthcare Data: A Systematic Review
Importance: Preeclampsia is a leading cause of maternal morbidity and mortality globally. As real‐world data sources are increasingly used for maternal health surveillance and pharmacoepidemiologic studies, valid algorithms are essential for accurately identifying preeclampsia in routinely collected healthcare data. Objective: To identify and characterize algorithms used to ascertain preeclampsia in population‐based healthcare databases, summarize validation metrics, and describe the range of reported prevalence estimates. Evidence Review: Following PRISMA guidelines of 2021, PubMed was searched for studies published from January 1, 2010, to July 1, 2025. Observational studies using reproducible code‐based algorithms to identify preeclampsia in routinely collected healthcare data were included. Screening and full‐text review were performed in duplicate, with discrepancies resolved by a third reviewer. Data extraction focused on algorithm definitions, coding systems, validation methods, and epidemiologic estimates. A total of 289 studies met inclusion criteria, including 13 validation studies. Findings: Across included studies, 43.6% used Nordic nationwide registries, 30.1% used claims databases, and 12.1% used electronic health records. ICD‐10 O14.x was used in nearly all studies; inclusion of O11.x and O15.x varied. Validation studies consistently demonstrated high specificity (> 90%) but low sensitivity (≤ 80%), reflecting under‐ascertainment when relying solely on diagnosis codes. More than 70% of studies did not report start or end points for the time window of ascertainment. Reported prevalence ranged from 0.6% to 6.6% across case definitions and settings. The prevalence of severe preeclampsia ranged from 0.6% to 2.2%. Algorithms including O11.x, O14.x, and O15.x showed improved sensitivity in some settings. Conclusions and Relevance: Algorithms for identifying preeclampsia in real‐world data are highly specific but variably sensitive, with substantial heterogeneity in coding definitions and ascertainment windows. Standardized reporting and consistent inclusion of O11.x, O14.x, and O15.x may improve comparability, reproducibility, and the accuracy of epidemiologic estimates across data sources. High‐specificity algorithms may be particularly useful for comparative safety studies, whereas potential under‐ascertainment should be considered when estimating incidence or prevalence.
- Open Access
- 18 September 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (9) , e70196
A Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental Outcomes
Purpose: Investigating pediatric neurodevelopmental outcomes (NDO) in studies using secondary data is often challenging due to heterogeneous clinical definitions and medical coding systems. This study aims to identify the algorithms used to define NDO in studies using electronic healthcare data through a systematic literature review. Methods: A search strategy was developed to identify studies on NDO that describe phenotype algorithms from January 1, 2010, to March 10, 2025. The search strategy included terms to identify studies containing algorithms for NDO as an outcome, routinely collected healthcare data, epidemiologic designs likely to incorporate algorithms, and pregnant individuals and/or infants/children. Two independent reviewers assessed eligibility criteria and performed data extraction, with inconsistencies reviewed by a third reviewer. Descriptive statistics were used to summarize categorical and continuous variables appropriately. Results: The review included 156 publications that implemented algorithms for NDO, with 18 of these studies validating the outcomes. Most publications studied autism spectrum disorder (ASD) ( n = 103, 65.6%) and attention deficit hyperactivity disorder (ADHD) ( n = 72, 45.9%) either as a single outcome or as a composite. Conclusions: Instead of presenting NDO as a composite outcome, it is recommended to present multiple single outcomes. Validated outcomes in data from Nordic countries demonstrate a high positive predictive value when using one code for diagnoses, while more complex algorithms are required for US data. Clearly detailing and establishing the time of assessment for each NDO is critical to inform valid epidemiological estimates.
- 18 September 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (9) , e70196
Open AccessA Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental Outcomes
Purpose: Investigating pediatric neurodevelopmental outcomes (NDO) in studies using secondary data is often challenging due to heterogeneous clinical definitions and medical coding systems. This study aims to identify the algorithms used to define NDO in studies using electronic healthcare data through a systematic literature review. Methods: A search strategy was developed to identify studies on NDO that describe phenotype algorithms from January 1, 2010, to March 10, 2025. The search strategy included terms to identify studies containing algorithms for NDO as an outcome, routinely collected healthcare data, epidemiologic designs likely to incorporate algorithms, and pregnant individuals and/or infants/children. Two independent reviewers assessed eligibility criteria and performed data extraction, with inconsistencies reviewed by a third reviewer. Descriptive statistics were used to summarize categorical and continuous variables appropriately. Results: The review included 156 publications that implemented algorithms for NDO, with 18 of these studies validating the outcomes. Most publications studied autism spectrum disorder (ASD) ( n = 103, 65.6%) and attention deficit hyperactivity disorder (ADHD) ( n = 72, 45.9%) either as a single outcome or as a composite. Conclusions: Instead of presenting NDO as a composite outcome, it is recommended to present multiple single outcomes. Validated outcomes in data from Nordic countries demonstrate a high positive predictive value when using one code for diagnoses, while more complex algorithms are required for US data. Clearly detailing and establishing the time of assessment for each NDO is critical to inform valid epidemiological estimates.
- Open Access
- 15 February 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (2) , e5764
Where are the data to assess the safety of paternal drug exposure? A systematic review of secondary databases: A contribution from IMI concePTION
Background: Most studies assessing the safety of parental drug exposures during pregnancy and around the time of conception describe the effects of maternal exposure. Recent publications have raised awareness of the need for additional research regarding the safety of paternal drug exposures on pregnancy outcomes.Objectives: To identify and describe studies that use secondary databases in paternal drug safety studies and to describe the secondary databases that were used.Methods: A systematic review of studies assessing paternal medication exposure and pregnancy and infant outcomes using secondary databases was performed. In addition, the secondary databases used for these studies was described. Literature search was conducted using Embase, Web of Science, and PubMed, over the period January 1, 2012 to April 30, 2023. For each eligible study, paternal drug exposure, outcome, and data source characteristics were extracted in a data extraction form.Results: After reviewing the literature, 17 studies met inclusion criteria. The medications assessed for paternal safety were anti‐rheumatic drugs (n = 10), anti‐depressants (n = 3), anticonvulsants (n = 2), and anti‐diabetes medications (n = 2). Pregnancy safety outcomes included congenital malformations, birth weight, and developmental disorders. The studies used five different databases across Europe and North America. The included studies used databases from Denmark (n = 12), Norway (n = 2), Sweden (n = 1), Canada (n = 1), and the United States (n = 1). The European studies utilized national patient registers that linked fathers to births and prescription histories. The North American databases used included insurance claims and electronic health records.Conclusions: Our review shows that few studies have been completed on paternal medication exposures and pregnancy outcomes, despite the availability of secondary databases that contain data necessary to link fathers to infants. More research on the potential adverse impacts of paternal medication exposures is needed.
- 15 February 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (2) , e5764
Open AccessWhere are the data to assess the safety of paternal drug exposure? A systematic review of secondary databases: A contribution from IMI concePTION
Background: Most studies assessing the safety of parental drug exposures during pregnancy and around the time of conception describe the effects of maternal exposure. Recent publications have raised awareness of the need for additional research regarding the safety of paternal drug exposures on pregnancy outcomes.Objectives: To identify and describe studies that use secondary databases in paternal drug safety studies and to describe the secondary databases that were used.Methods: A systematic review of studies assessing paternal medication exposure and pregnancy and infant outcomes using secondary databases was performed. In addition, the secondary databases used for these studies was described. Literature search was conducted using Embase, Web of Science, and PubMed, over the period January 1, 2012 to April 30, 2023. For each eligible study, paternal drug exposure, outcome, and data source characteristics were extracted in a data extraction form.Results: After reviewing the literature, 17 studies met inclusion criteria. The medications assessed for paternal safety were anti‐rheumatic drugs (n = 10), anti‐depressants (n = 3), anticonvulsants (n = 2), and anti‐diabetes medications (n = 2). Pregnancy safety outcomes included congenital malformations, birth weight, and developmental disorders. The studies used five different databases across Europe and North America. The included studies used databases from Denmark (n = 12), Norway (n = 2), Sweden (n = 1), Canada (n = 1), and the United States (n = 1). The European studies utilized national patient registers that linked fathers to births and prescription histories. The North American databases used included insurance claims and electronic health records.Conclusions: Our review shows that few studies have been completed on paternal medication exposures and pregnancy outcomes, despite the availability of secondary databases that contain data necessary to link fathers to infants. More research on the potential adverse impacts of paternal medication exposures is needed.
- Open Access
- 11 January 2024
- Published by Wiley in Journal of Pregnancy
- Vol. 2024, 1-13
Drug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION
Purpose. Studies focusing on safety outcomes typically require large populations to comprehensively characterise the patient groups exposed to the medicines under investigation. However, there is often less information for subpopulations, such as pregnant or breastfeeding women, particularly when new medicines are considered. It is important to understand what information can be obtained from drug utilization studies (DUS) involving pregnant women in the early years postmarketing to provide supportive information for safety studies. The aims of this literature review are to (1) identify and review DUS for new medicines in pregnancy and breastfeeding and (2) list and summarise key information items to be reported in a DUS for new medicines in pregnancy. Methods. To identify postmarketing DUS of new prescription medicines or enantiomers in pregnancy, a systematic literature review was undertaken in PubMed and Embase between January 2015 and June 2022. In addition, the complete database of the ENCePP EU PAS Register was systematically searched to June 2022. Results. We identified 11 published DUS on new medicines in pregnancy from the ENCePP EU PAS Register and none from other sources. No studies on breastfeeding were identified. The 11 identified publications reported the medicine’s use for the first 3 to 5 years after marketing approval. No reports assessed utilization in the first 3 years of approval. It was usual to issue interim reports annually (7 studies). All studies concerned conditions managed in ambulatory care (primary care and outpatient facilities) and included some primary care prescribing. Most ( ) only had prescribing/dispensing data available at individual level for ambulatory care; outpatient prescribing was included in three of these studies Three studies held a limited amount of in-hospital prescribing data. A DUS can confirm at an early stage whether there are sufficient exposed pregnancies in available data sources to ensure a safety study is powered to detect a difference in the prevalence of adverse pregnancy or infant outcomes or if additional data from other databases are needed. A DUS may also help address methodological considerations such as selection of comparators. DUS can be performed embedded in a DUS in the general population, in a cohort of women of childbearing age, or in a cohort of pregnant women. Conclusion. This review summarises key aspects of a DUS for new medicines in pregnancy. DUS for new medicines in pregnancy should be planned before marketing, scheduled for the first 3 to 5 years after release, with annual interim/progress reports, and reported in peer-reviewed journals. By offering detailed information on data sources, exposure timing, prevalence and location, coprescribing, comorbidities, coexposures, and demographics, a DUS will offer a firm foundation for safety studies and will help to contextualize spontaneous reporting of serious adverse events.
- 11 January 2024
- Published by Wiley in Journal of Pregnancy
- Vol. 2024, 1-13
Open AccessDrug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION
Purpose. Studies focusing on safety outcomes typically require large populations to comprehensively characterise the patient groups exposed to the medicines under investigation. However, there is often less information for subpopulations, such as pregnant or breastfeeding women, particularly when new medicines are considered. It is important to understand what information can be obtained from drug utilization studies (DUS) involving pregnant women in the early years postmarketing to provide supportive information for safety studies. The aims of this literature review are to (1) identify and review DUS for new medicines in pregnancy and breastfeeding and (2) list and summarise key information items to be reported in a DUS for new medicines in pregnancy. Methods. To identify postmarketing DUS of new prescription medicines or enantiomers in pregnancy, a systematic literature review was undertaken in PubMed and Embase between January 2015 and June 2022. In addition, the complete database of the ENCePP EU PAS Register was systematically searched to June 2022. Results. We identified 11 published DUS on new medicines in pregnancy from the ENCePP EU PAS Register and none from other sources. No studies on breastfeeding were identified. The 11 identified publications reported the medicine’s use for the first 3 to 5 years after marketing approval. No reports assessed utilization in the first 3 years of approval. It was usual to issue interim reports annually (7 studies). All studies concerned conditions managed in ambulatory care (primary care and outpatient facilities) and included some primary care prescribing. Most ( ) only had prescribing/dispensing data available at individual level for ambulatory care; outpatient prescribing was included in three of these studies Three studies held a limited amount of in-hospital prescribing data. A DUS can confirm at an early stage whether there are sufficient exposed pregnancies in available data sources to ensure a safety study is powered to detect a difference in the prevalence of adverse pregnancy or infant outcomes or if additional data from other databases are needed. A DUS may also help address methodological considerations such as selection of comparators. DUS can be performed embedded in a DUS in the general population, in a cohort of women of childbearing age, or in a cohort of pregnant women. Conclusion. This review summarises key aspects of a DUS for new medicines in pregnancy. DUS for new medicines in pregnancy should be planned before marketing, scheduled for the first 3 to 5 years after release, with annual interim/progress reports, and reported in peer-reviewed journals. By offering detailed information on data sources, exposure timing, prevalence and location, coprescribing, comorbidities, coexposures, and demographics, a DUS will offer a firm foundation for safety studies and will help to contextualize spontaneous reporting of serious adverse events.
- Top Cited PapersOpen Access
- 16 January 2023
- Published by Springer Nature in Systematic Reviews
- Vol. 12 (1) , 1-9
Global prevalence of Rett syndrome: systematic review and meta-analysis
Background: Rett syndrome is a rare, severe neurodevelopmental disorder. Almost all cases occur in girls, in association with spontaneous (non-inherited) mutations involving the methyl-CpG-binding protein 2 gene located on the X chromosome. Diagnostic criteria for typical Rett syndrome require a period of regression, followed by recovery or stabilization, and fulfillment of all four main criteria (loss of purposeful hand skills, loss of spoken language, gait abnormalities, and stereotypic hand movements). Our objective was to estimate the prevalence of Rett syndrome in the general population, stratified by sex. Methods: We conducted a search of PubMed, Embase, Web of Science, Cochrane Library, LILACS, and LIVIVO to retrieve studies published in English between Jan. 1, 2000, and June 30, 2021. Pooled prevalence with a 95% confidence interval (CI) was estimated using a random-effects meta-analysis based on a generalized linear mixed model with a logit link. Results: Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women and 673 Rett syndrome cases. The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001). Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs. Conclusion: These findings may facilitate planning of therapeutic trials in this indication in terms of target sample size and accrual times.
- 16 January 2023
- Published by Springer Nature in Systematic Reviews
- Vol. 12 (1) , 1-9
Top Cited PapersOpen AccessGlobal prevalence of Rett syndrome: systematic review and meta-analysis
Background: Rett syndrome is a rare, severe neurodevelopmental disorder. Almost all cases occur in girls, in association with spontaneous (non-inherited) mutations involving the methyl-CpG-binding protein 2 gene located on the X chromosome. Diagnostic criteria for typical Rett syndrome require a period of regression, followed by recovery or stabilization, and fulfillment of all four main criteria (loss of purposeful hand skills, loss of spoken language, gait abnormalities, and stereotypic hand movements). Our objective was to estimate the prevalence of Rett syndrome in the general population, stratified by sex. Methods: We conducted a search of PubMed, Embase, Web of Science, Cochrane Library, LILACS, and LIVIVO to retrieve studies published in English between Jan. 1, 2000, and June 30, 2021. Pooled prevalence with a 95% confidence interval (CI) was estimated using a random-effects meta-analysis based on a generalized linear mixed model with a logit link. Results: Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women and 673 Rett syndrome cases. The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001). Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs. Conclusion: These findings may facilitate planning of therapeutic trials in this indication in terms of target sample size and accrual times.
- Top Cited PapersOpen Access
- 23 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Long-COVID in children and adolescents: a systematic review and meta-analyses
The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥ 12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.
- 23 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Top Cited PapersOpen AccessLong-COVID in children and adolescents: a systematic review and meta-analyses
The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥ 12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.
- Open Access
Long-COVID in Children and Adolescents: A Systematic Review and Meta-analyses
The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I 2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8,373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.
Open AccessLong-COVID in Children and Adolescents: A Systematic Review and Meta-analyses
The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I 2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8,373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.
- Top Cited PapersOpen Access
- 9 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1)
More than 50 long-term effects of COVID-19: a systematic review and meta-analysis
COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data published before the 1st of January 2021, with a minimum of 100 patients. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. PRISMA guidelines were followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included (age 17–87 years). The included studies defined long-COVID as ranging from 14 to 110 days post-viral infection. It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). Multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.
- 9 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1)
Top Cited PapersOpen AccessMore than 50 long-term effects of COVID-19: a systematic review and meta-analysis
COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data published before the 1st of January 2021, with a minimum of 100 patients. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. PRISMA guidelines were followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included (age 17–87 years). The included studies defined long-COVID as ranging from 14 to 110 days post-viral infection. It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). Multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.
- 1 May 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 124, 358-369
Molecular genetics of substance use disorders: An umbrella review
- 1 May 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 124, 358-369
Molecular genetics of substance use disorders: An umbrella review
- 1 April 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (2) , 742-749
A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project
The present study aims to summarize the safety profile of the medications used to treat migraine during pregnancy by performing a systematic review and meta-analyses. The term “migrain*” combined with pregnancy terms were used to search Embase, PubMed, PsychInfo, Scopus, and Web of Science through 31 December 2020. Pooled prevalences of untreated and treated migraine patients were estimated using MetaXL software. Pooled odds ratios (OR) using random effects models were estimated in RevMan 5. All the identified studies assessed medications used to treat acute migraine. The pooled prevalence of adverse pregnancy outcomes in patients prescribed any migraine medication ranged from 0.4% (95% CI 0.2–0.7%) for stillbirth to 12.0% (95%CI 7.8–16.9%) for spontaneous abortions. Among untreated patients with migraine, the pooled prevalence of the assessed pregnancy outcomes ranged from 0.6% (95% CI: 0–1.7%) for stillbirth to 10.4% (95% CI: 8.9–12%) for gestational age < 37 weeks. Given the limited data, it was only possible to perform OR meta-analyses for triptans. The adjusted ORs for triptan users compared the general population were: for major malformations 1.07 (95%CI: 0.83–1.39, p = 0.60); birth weight < 2500g 1.18 (95%CI: 0.94–1.48, p = 0.16); gestational age < 37 weeks 1.49 (95% CI: 0.37–6.08, p = 0.58). In conclusion, triptans do not appear to increase the risk of pregnancy outcomes when compared to the general population. It was not possible to assess other migraine medications. Further studies are needed to investigate the safety of individual medications of acute and prophylactic migraine treatment among pregnant women.
- 1 April 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (2) , 742-749
A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project
The present study aims to summarize the safety profile of the medications used to treat migraine during pregnancy by performing a systematic review and meta-analyses. The term “migrain*” combined with pregnancy terms were used to search Embase, PubMed, PsychInfo, Scopus, and Web of Science through 31 December 2020. Pooled prevalences of untreated and treated migraine patients were estimated using MetaXL software. Pooled odds ratios (OR) using random effects models were estimated in RevMan 5. All the identified studies assessed medications used to treat acute migraine. The pooled prevalence of adverse pregnancy outcomes in patients prescribed any migraine medication ranged from 0.4% (95% CI 0.2–0.7%) for stillbirth to 12.0% (95%CI 7.8–16.9%) for spontaneous abortions. Among untreated patients with migraine, the pooled prevalence of the assessed pregnancy outcomes ranged from 0.6% (95% CI: 0–1.7%) for stillbirth to 10.4% (95% CI: 8.9–12%) for gestational age < 37 weeks. Given the limited data, it was only possible to perform OR meta-analyses for triptans. The adjusted ORs for triptan users compared the general population were: for major malformations 1.07 (95%CI: 0.83–1.39, p = 0.60); birth weight < 2500g 1.18 (95%CI: 0.94–1.48, p = 0.16); gestational age < 37 weeks 1.49 (95% CI: 0.37–6.08, p = 0.58). In conclusion, triptans do not appear to increase the risk of pregnancy outcomes when compared to the general population. It was not possible to assess other migraine medications. Further studies are needed to investigate the safety of individual medications of acute and prophylactic migraine treatment among pregnant women.